Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mirna Therapeutics is First to Advance MicroRNA into the Clinic for Cancer

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
Phase 1 clinical trial of anticancer drug MRX34 underway.

Mirna Therapeutics, Inc. announced that it has initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 trial is being conducted in patients with unresectable primary liver cancer or metastatic cancer with liver involvement.

“The initiation of this clinical trial is a landmark event for cancer drug development,” said Paul Lammers, M.D., President and Chief Executive Officer of Mirna Therapeutics. “Scientists at Mirna were among the first to elucidate the promise of tumor suppressor miRNAs as new therapeutic candidates. The preclinical profile of MRX34 across a range of tumors strongly suggests that miRNA-based therapeutics may represent a potent, new class of anticancer drugs working through a mechanism that affects multiple oncogenic pathways simultaneously.”

“Results from this initial clinical trial will be used to evaluate the safety of MRX34, and help us evaluate the potential of this compound for further clinical study,” said Andrew Brenner, M.D., Ph.D., medical oncologist and assistant professor in the School of Medicine at The University of Texas Health Science Center at San Antonio, and principal investigator on the study being conducted at the Cancer Therapy & Research Center at the Health Science Center. “We are excited to be the first to bring this new and innovative therapeutic approach to our patients. We look forward to reviewing the clinical data and to furthering the study of miRNA-based cancer therapeutics.”

The Phase 1 MRX34 study will follow a standard oncology study design, consisting of an initial dose-escalation phase followed by an enrichment phase, and is expected to enroll up to 48 patients in total. MRX34 is a miRNA “mimic” of tumor suppressor miR-34 delivered using a liposomal delivery formulation in-licensed from Marina Biotech.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mirna Therapeutics and Horizon Discovery Uncover Important Tumor Suppressor Pathway
Paper reports new findings on tumor suppressor miR-34 relationship with p53 and p21 cancer pathways.
Thursday, June 27, 2013
Mirna Therapeutics Presents Preclinical Data on Lead Product Candidate
Mirna Therapeutics, Inc. announced that new preclinical data from its lead product candidate will be presented this week at the Keystone conference on Non-coding RNAs in Development and Cancer.
Thursday, January 24, 2013
Scientific News
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!